In summary, the present study demonstrates that metformin improves hyperglycemia- and obesity-associated endothelial dysfunction by inhibiting YAP–JNK pathway-related inflammation via activating AMPK. Here, YAP1 is linked to obesity due to melanocortin 4 receptor deficiency.